Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 1/2017

Open Access 01-07-2017 | Review

Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer’s Disease

Authors: Shieh-Yueh Yang, Ming-Jang Chiu, Ta-Fu Chen, Herng-Er Horng

Published in: Neurology and Therapy | Special Issue 1/2017

Login to get access

Abstract

Alzheimer’s disease (AD) is the most common form of dementia. The development of assay technologies able to diagnose early-stage AD is important. Blood tests to detect biomarkers, such as amyloid and total Tau protein, are among the most promising diagnostic methods due to their low cost, low risk, and ease of operation. However, such biomarkers in blood occur at extremely low levels and are difficult to detect precisely. In the early 2000s, a highly sensitive assay technology, immunomagnetic reduction (IMR), was developed. IMR involves the use of antibody-functionalized magnetic nanoparticles dispersed in aqueous solution. The concentrations of detected molecules are converted to reductions in the ac magnetic susceptibility of this reagent due to the association between the magnetic nanoparticles and molecules. To achieve ultra-high sensitivity, a high-Tc superconducting-quantum-interference-device (SQUID) ac magnetosusceptometer was designed and applied to detect the tiny reduction in the ac magnetic susceptibility of the reagent. Currently, a 36-channeled high-Tc SQUID-based ac magnetosusceptometer is available. Using the reagent and this analyzer, extremely low concentrations of amyloid and total Tau protein in human plasma could be detected. Further, the feasibility of identifying subjects in early-stage AD via assaying plasma amyloid and total Tau protein is demonstrated. The results show a diagnostic accuracy for prodromal AD higher than 80% and reveal the possibility of screening for early-stage AD using SQUID-based IMR.
Literature
1.
Katzman R. The prevalence and malignancy of Alzheimer disease: a major killer. Arch Neurol. 1976;33:217–8.CrossRefPubMed
2.
Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DE, Hall KS, Gao S, Unverzagt FW, Langa KM, Larson EB, White LR. Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States. Alzheimer’s Dementia. 2011;7:80–93.CrossRefPubMedPubMedCentral
3.
4.
Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2015;11:332–84.CrossRef
5.
Stefanacci RG. The costs of Alzheimer’s disease and the value of effective therapies. Am J Manag Care. 2011;17:S356–62.PubMed
6.
Bloom BS, de Pouvourville N, Straus WL. Cost of illness of Alzheimer’s disease: how useful are current estimates? Gerontologist. 2003;43:158–64.CrossRefPubMed
7.
Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN. Alzheimer’s prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimer’s Dis. 2011;26:321–9.
8.
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer’s disease neuroimaging initiative (ADNI). Neurology. 2010;74:201–9.CrossRefPubMedPubMedCentral
9.
Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, Hänninen LBT, Jula A, Laatikainen T, Lindström J, Mangialasche F, Nissinen A, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H. The finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER): study design and progress. Alzheimer’s Dementia. 2013;9:657–65.CrossRefPubMed
10.
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–5.CrossRefPubMed
11.
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National institute on aging–Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimer’s Dementia. 2012;8:1–13.CrossRefPubMedPubMedCentral
12.
Leinonen V, Koivisto AM, Savolainen S, Rummukainen J, Tamminen JN, Tillgren T, Vainikka S, Pyykkö OT, Mölsä J, Fraunberg M, Pirttilä T, Jääskeläinen JE, Soininen H, Rinne J, Alafuzoff I. Amyloid and tau proteins in cortical brain biopsy and Alzheimer’s disease. Ann Neurol. 2010;68:446–53.CrossRefPubMed
13.
Holm A, Savolainen S, Alafuzoff I. Brain biopsy prior to treatment of Alzheimer’s disease. Minim Invasive Neurosurg. 2003;46:161–4.CrossRefPubMed
14.
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349:704–6.CrossRefPubMed
15.
16.
17.
Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970;11:205–42.CrossRefPubMed
18.
Iqbal GIK, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084–9.PubMed
19.
Arrigada PA, Growdon JH, Hedley-White ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42:631–9.CrossRef
20.
de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron. 2012;73:685–97.CrossRefPubMedPubMedCentral
21.
Henneman WJP, Sluimer JD, Barnes J, van der Flier WM, Sluimer IC, Fox NC, Scheltens P, Vrenken H, Barkhof F. Hippocampal atrophy rates in Alzheimer disease. Neurology. 2009;72:999–1007.CrossRefPubMedPubMedCentral
22.
Chiu MJ, Chen YF, Chen TF, Yang SY, Yang FP, Tseng TW, Chieh JJ, Chen JC, Tzen KY, Hua MS, Horng HE. Plasma tau as a window to the brain—negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer’s disease. Hum Brain Mapp. 2014;35:3132–42.CrossRefPubMed
23.
Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Mitchell K, Pappas V, Thies WH. Appropriate use criteria for amyloid PET. Alzheimer’s Dementia. 2013;9:e-1–-16.CrossRef
24.
Tzen KY, Yang SY, Chen TF, Cheng TW, Horng HE, Wen HP, Huang YY, Shiue CY, Chiu MJ. Plasma Aβ but not tau related to brain PiB retention in early Alzheimer’s disease. ACS Chem Neurosci. 2014;5:830–6.CrossRefPubMed
25.
O’Brien JT, Herholz K. Amyloid imaging for dementia in clinical practice. BMC Med. 2015;13:163-1–3.
26.
Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer’s disease. Curr Neurol Neurosci Rep. 2014;14:500–6.CrossRefPubMed
27.
Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TLS, Ances BM. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease. Sci Trans Med. 2016;8:338aa66.CrossRef
28.
Vemuri P, Jack CR Jr. Role of structural MRI in Alzheimer’s disease. Alzheimer’s Res Ther. 2010;2:23-1–-10.
29.
30.
Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW. MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132:1067–77.CrossRefPubMedPubMedCentral
31.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease. Neurology. 1984;34:939–44.CrossRefPubMed
32.
Moms JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark DC. The consortium to establish a registry for Alzheimer’s disease (CERAD). Neurology. 1989;39:1159–65.CrossRef
33.
Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology. 2005;64:1853–9.CrossRefPubMed
34.
Braaten AJ, Parsons TD, McCue R, Sellers A, Burns WJ. Neurocognitive differential diagnosis of dementing diseases: alzheimer’s dementia, vascular dementia, frontotemporal dementia, and major depressive disorder. Int J Neurosci. 2006;116:1271–93.CrossRefPubMed
35.
Chapman RM, Mapstone M, Porsteinsson AP, Gardner MN, McCrary JW, DeGrush E, Reilly LA, Sandoval TC, Guillily MD. Diagnosis of Alzheimer’s disease using neuropsychological testing improved by multivariate analyses. J Clin Exp Neuropsychol. 2010;32:793–808.CrossRefPubMedPubMedCentral
36.
Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:006171-1–-18.CrossRef
37.
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS amyloid-β in Alzheimer’s disease. Science. 2010;330:1774–7.CrossRefPubMedPubMedCentral
38.
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–9.CrossRefPubMed
39.
Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373–9.CrossRefPubMed
40.
Kim WH, Lee S, Hall GF. Secretion of human tau fragments resembling CSF-tau in Alzheimer’s disease is modulated by the presence of the exon 2 insert. FEBC Lett. 2010;584:3085–8.CrossRef
41.
Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382–9.CrossRefPubMed
42.
Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673–80.CrossRefPubMed
43.
Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, Andreasen N, Zetterberg H, Blennow K. Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer’s disease. PLoS One. 2013;8:e66381.CrossRefPubMedPubMedCentral
44.
Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, Peoch K, Sablonnière B, Kastanenka KV, Delaby C, Pasquier F, Touchon J, Hugon J, Paquet C, Lehmann S. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer’s Res Ther. 2015;7:30-1–9.
45.
46.
Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner M. Diagnostic accuracy of CSF Aβ42 and florbetapir PET for Alzheimer’s disease. Ann Clin Transl Neurol. 2014;1:534–43.CrossRefPubMedPubMedCentral
47.
Lautner R, Palmqvist S, Mattsson N. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry. 2014;71:1183–91.CrossRefPubMed
48.
Chiu MJ, Yang SY, Chen TF, Chieh JJ, Huang TZ, Yip PK, Yang HC, Cheng TW, Chen YF, Hua MS, Horng HE. New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer’s disease. Curr Alzheimer’s Res. 2012;9:1142–8.CrossRef
49.
Chiu MJ, Yang SY, Horng HE, Yang CC, Chen TF, Chieh JJ, Chen HH, Chen TC, Ho CS, Chang SF, Liu HC, Hong CY, Yang HC. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chem Neurosci. 2013;4:1530–6.CrossRefPubMedPubMedCentral
50.
Sehlin D, Sölvander S, Paulie S, Brundin R. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J Alzheimer’s Dis. 2010;21:1295–301.CrossRef
51.
Azriel R, Gaz E. Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. J Biol Chem. 2001;276:34156–61.CrossRefPubMed
52.
Trysberg E, Höglund K, Svenungsson E, Blennow K, Tarkowski A. Decreased levels of soluble amyloid β-protein precursor and β-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Res Ther. 2004;6:R129–36.CrossRefPubMedPubMedCentral
53.
Hong CY, Wu CC, Chiu YC, Yang SY, Horng HE, Yang HC. Magnetic susceptibility reduction method for magnetically labeled immunoassay. Appl Phys Lett. 2006;88:212512-1–3.
54.
Chieh JJ, Yang SY, Jian ZF, Wang WC, Horng HE, Yang HC, Hong CY. Hyper-high-sensitivity wash-free magnetoreduction assay on biomolecules using high-Tc superconducting quantum interference devices. J Appl Phys. 2008;103:014703-1–6.CrossRef
55.
Jiang W, Yang HC, Yang SY, Horng HE, Hung JC, Chen YC, Hong CY. Preparation and properties of superparamagnetic nanoparticles with narrow size distribution and biocompatible. J Magn Magn Mater. 2004;283:210–4.CrossRef
56.
Huang KW, Yang SY, Yu CY, Chieh JJ, Yang CC, Horng HE, Hong CY, Yang HC, Wu CC. Exploration of the relationship between the tumor burden and the concentration of vascular endothelial growth factor in liver-cancer-bearing animals using immunomagnetic reduction assay. J Biomed Nanotechnol. 2011;7:535–41.CrossRefPubMed
57.
Yang SY, Chiu MJ, Lin CH, Horng HE, Yang CC, Chieh JJ, Chen HH, Liu BH. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. J Nanobiotechnol. 2016;14:41–7.CrossRef
58.
Yang SY, Chieh JJ, Wang WC, Yu CY, Lan CB, Chen JH, Horng HE, Hong CY, Yang HC. Ultra-highly sensitive and wash-free bio-detections for H5N1 virus via magnetoreduction assays. J Virol Methods. 2008;153:250–2.CrossRefPubMed
59.
Mondello S, Buki A, Barzo P, Randall J, Provuncher G, Hanlon D, Wilson D, Kobeissy F, Jeromin A. CSF and plasma amyloid-β temporal profiles and relationships with neurological status and mortality after severe traumatic brain injury. Sci Rep. 2014;4:6446-1–6.
60.
Janelidze S, Stomrud E, Palmgvist S, Zetterberg H, van Western D, Jeromin A, Song L, Hanlon D, Hehir CAT, Baker D, Blennow K, Hasson O. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci Rep. 2016;6:26801-1–-11.CrossRef
61.
Todd J, Freese B, Lu A, Held D, Morey J, Livingston R, Goix P. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem. 2007;53:1990–5.CrossRefPubMed
62.
Apple FS, Steffen LM, Pearce LA, Murakami MM, Luepker RV. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota heart survey. Clin Chem. 2012;58:930–5.CrossRefPubMed
63.
Horng HE, Yang SY, Huang YW, Jiang W, Hong CY, Yang HC. Nanomagnetic particles for SQUID-based magnetically labeled immunoassay. IEEE Trans Appl Supercond. 2005;15:668–71.CrossRef
64.
Frenkel J. Theory of liquid. New York: Dover; 1955.
65.
Brown WF Jr. Thermal fluctuations of a single-domain particle. Phys Rev. 1963;130:1677–86.CrossRef
66.
Yang CC, Yang SY, Chen HH, Weng WL, Horng HE, Chieh JJ, Hong CY, Yang HC. Effect of molecule-particle binding on the reduction in the mixed-frequency alternating current magnetic susceptibility of magnetic bio-reagents. J Appl Phys. 2012;112:024704-1–4.
67.
Chieh JJ, Yang SY, Horng HE, Yu CY, Lee CL, Wu HL, Hong CY, Yang HC. Immunomagnetic reduction assay using high-Tc superconducting-quantum-interference-device-based magnetosusceptometry. J Appl Phys. 2010;107:074903-1–5.CrossRef
68.
Yang SY, Chieh JJ, Yang CC, Liao SH, Chen HH, Horng HE, Yang HC, Hong CY, Chiu MJ, Chen TF, Huang KW, Wu CC. Clinic applications in assaying ultra-low-concentration bio-markers using HTS SQUID-based AC magnetosusceptometer. IEEE Trans Appl Supercond. 2013;23:1600604–7.CrossRef
69.
Yang CC, Yang SY, Chieh JJ, Horng HE, Hong CY, Yang HC. Universal behavior of biomolecule-concentration-dependent reduction in AC magnetic susceptibility of bioreagents. IEEE Magn Lett. 2012;3:1500104-1–4.CrossRef
70.
Yang CC, Yang SY, Chieh JJ, Horng HE, Hong CY, Yang HC, Chen KH, Shih BY, Chen TF, Chiu MJ. Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer’s disease in vitro. ACS Chem Neurosci. 2011;2:500–5.CrossRefPubMedPubMedCentral
71.
Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958–64.CrossRefPubMed
72.
Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2003;64:343–9.CrossRef
73.
Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R. Peripheral Aβ subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci USA. 2008;105:14052–7.CrossRefPubMedPubMedCentral
74.
Ruiz A, Pesini P, Espinosa A, Pérez-Grijalba V, Valero S, Sotolongo-Grau O, Alegret M, Monleón I, Lafuente A, Buendía M, Ibarria M, Ruiz S, Hernández I, José IS, Tárraga L, Boada M, Sarasa M. Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer’s disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates. PLoS One. 2013;8:e81334-1–9.
75.
Wang T, Xiao S, Liu Y, Lin Z, Su N, Li X, Li G, Zhang M, Fang Y. The efficacy of plasma biomarkers in early diagnosis of Alzheimer’s disease. Int J Geriatr Psychiatry. 2013;29:713–9.CrossRefPubMed
76.
Wang T, Xiao S, Liu Y, Lin Z, Su N, Li X, Li G, Zhang M, Fang Y. The efficacy of plasma biomarkers in early diagnosis of Alzheimer’s disease. Int J Geriatr Psychiatry. 2014;29:713–9.CrossRefPubMed
77.
Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis. J Neurol. 2013;260:2722–7.CrossRefPubMedPubMedCentral
78.
Yang SY, Wang WC, Lan CB, Chen CH, Chieh JJ, Horng HE, Hong CY, Yang HC, Tsai CP, Yang CY, Cheng IC, Chung WC. Magnetically enhanced high-specificity virus detection using bio-activated magnetic nanoparticles with antibodies as labeling markers. J Virol Methods. 2010;164:14–8.CrossRefPubMed
79.
Andreasen N, Vanmechelen E, de Voorde AV, Davidsson P, Hesse C, Tarvonen S, Räihä I, Sourander L, Winblad B, Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998;64:298–305.CrossRefPubMedPubMedCentral
80.
Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer’s disease. Front Aging Neurosci. 2013;5:6-1–-11.CrossRef
Metadata
Title
Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer’s Disease
Authors
Shieh-Yueh Yang
Ming-Jang Chiu
Ta-Fu Chen
Herng-Er Horng
Publication date
01-07-2017
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue Special Issue 1/2017
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-017-0075-7

Other articles of this Special Issue 1/2017

Neurology and Therapy 1/2017 Go to the issue

Review

A Review of Biomarkers for Alzheimer’s Disease in Down Syndrome

Review

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies

Review

Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data

Editorial

Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer’s Disease and Related Disorders

Review

The Study of Postmortem Human Synaptosomes for Understanding Alzheimer’s Disease and Other Neurological Disorders: A Review

Review

A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?